These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 21197688)

  • 1. [Heart failure. Heart rate control prevents clinical complications].
    Einecke D
    MMW Fortschr Med; 2010 Sep; 152(37):12-3. PubMed ID: 21197688
    [No Abstract]   [Full Text] [Related]  

  • 2. Effects on outcomes of heart rate reduction by ivabradine in patients with congestive heart failure: is there an influence of beta-blocker dose?: findings from the SHIFT (Systolic Heart failure treatment with the I(f) inhibitor ivabradine Trial) study.
    Swedberg K; Komajda M; Böhm M; Borer J; Robertson M; Tavazzi L; Ford I;
    J Am Coll Cardiol; 2012 May; 59(22):1938-45. PubMed ID: 22617188
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study.
    Swedberg K; Komajda M; Böhm M; Borer JS; Ford I; Dubost-Brama A; Lerebours G; Tavazzi L;
    Lancet; 2010 Sep; 376(9744):875-85. PubMed ID: 20801500
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ivabradine in heart failure: hope or hype?
    Deedwania PC
    Am J Cardiovasc Drugs; 2012 Dec; 12(6):357-9. PubMed ID: 23181943
    [No Abstract]   [Full Text] [Related]  

  • 5. I(f) current and heart rate control.
    César LA
    Arq Bras Cardiol; 2007 Apr; 88(4):e99-e102. PubMed ID: 17546262
    [No Abstract]   [Full Text] [Related]  

  • 6. Effect of Selective Heart Rate Slowing in Heart Failure With Preserved Ejection Fraction.
    Pal N; Sivaswamy N; Mahmod M; Yavari A; Rudd A; Singh S; Dawson DK; Francis JM; Dwight JS; Watkins H; Neubauer S; Frenneaux M; Ashrafian H
    Circulation; 2015 Nov; 132(18):1719-25. PubMed ID: 26338956
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Heart rate as a risk factor in chronic heart failure (SHIFT): the association between heart rate and outcomes in a randomised placebo-controlled trial.
    Böhm M; Swedberg K; Komajda M; Borer JS; Ford I; Dubost-Brama A; Lerebours G; Tavazzi L;
    Lancet; 2010 Sep; 376(9744):886-94. PubMed ID: 20801495
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Update on ivabradine for heart failure.
    Borer JS; Tavazzi L
    Trends Cardiovasc Med; 2016 Jul; 26(5):444-9. PubMed ID: 26934996
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The importance of reducing heart rate in cardiovascular diseases: effects of Ivabradine.
    Vizzardi E; Bonadei I; D'Aloia A; Del Magro F; Piovanelli B; Bontempi L; Curnis A; Dei Cas L
    Minerva Med; 2011 Oct; 102(5):373-9. PubMed ID: 22193347
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Heart failure: A SHIFT from ion channels to clinical practice.
    Terracciano CM; Yacoub MH
    Nat Rev Cardiol; 2010 Dec; 7(12):669-70. PubMed ID: 21102629
    [No Abstract]   [Full Text] [Related]  

  • 11. SHIFTING the burden of heart failure.
    Cardiovasc J Afr; 2010; 21(5):302. PubMed ID: 20972527
    [No Abstract]   [Full Text] [Related]  

  • 12. Advances in the management of heart failure: the role of ivabradine.
    Müller-Werdan U; Stöckl G; Werdan K
    Vasc Health Risk Manag; 2016; 12():453-470. PubMed ID: 27895488
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ivabradine and outcomes in chronic heart failure.
    Kang SM; Won H; Hong N; Oh J
    Lancet; 2010 Dec; 376(9758):2069; author reply 2069-70. PubMed ID: 21168043
    [No Abstract]   [Full Text] [Related]  

  • 14. [Ivabradine -- a novel approach for heart rate lowering].
    Er F; Hoppe UC
    Dtsch Med Wochenschr; 2005 Jun; 130(24):1501-2. PubMed ID: 15942839
    [No Abstract]   [Full Text] [Related]  

  • 15. [Possibilities of reducing heart rate by I(f)-channel inhibitors].
    Hennersdorf MG
    Med Klin (Munich); 2006 Mar; 101 Suppl 1():150-2. PubMed ID: 16802542
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Coronary heart disease. Rapid heart rate has an unfavorable prognosis].
    Einecke D
    MMW Fortschr Med; 2008 Sep; 150(38):12-4. PubMed ID: 18983046
    [No Abstract]   [Full Text] [Related]  

  • 17. Ivabradine in heart failure: NICE guidance.
    Hardman SM
    Heart; 2014 Jan; 100(2):93-5. PubMed ID: 23781111
    [No Abstract]   [Full Text] [Related]  

  • 18. [Effect of ivabradine on heart rate, left ventricular function and levels of NT-proBNP in patients with chronic systolic heart failure--case reports].
    Vnitr Lek; 2012 Oct; 58(10):719-20. PubMed ID: 23233918
    [No Abstract]   [Full Text] [Related]  

  • 19. Ivabradine: in adults with chronic heart failure with reduced left ventricular ejection fraction.
    Perry CM
    Am J Cardiovasc Drugs; 2012 Dec; 12(6):415-26. PubMed ID: 23181944
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ivabradine: Current and Future Treatment of Heart Failure.
    Thorup L; Simonsen U; Grimm D; Hedegaard ER
    Basic Clin Pharmacol Toxicol; 2017 Aug; 121(2):89-97. PubMed ID: 28371247
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.